Etanercept tolerance in a patient with previous infliximab-induced hepatitis.
Becker
Heidemarie
H
Willeke
Peter
P
Domschke
Wolfram
W
Gaubitz
Markus
M
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D019693:Hepatitis, Autoimmune / Q000209:etiology* / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology / Q000627:therapeutic use*; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor / Q000276:immunology / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept
J Dermatolog Treat. 2005;16(5-6):347-9
16428159
Clin Rheumatol. 2007 Apr;26(4):578-81
16547695
Clin Rheumatol. 2008 Aug;27(8):1063-6
18563514